 Zacks Investment Research upgraded shares of Crinetics Pharmaceuticals NASDAQ:CRNX from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. The firm currently has 17.00 price objective on the stock. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and ... 